I am a
Home I AM A Search Login

Papers of the Week

2019 Nov-Dec

Allergol Immunopathol (Madr)



Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.


Rubini NPM, Ensina LFC, Silva EMK, Sano F, Solé D
Allergol Immunopathol (Madr). 2019 Nov-Dec; 47(6):515-522.
PMID: 31607407.


Chronic spontaneous urticaria (CSU) affects approximately 1% of the population, affecting both children and adults. Omalizumab (Oma) is a therapeutic option for patients with refractory forms of CSU.